Top-line results from a phase 3 trial of PaxMedica's (NASDAQ:PXMD) PAX-101 (intravenous suramin) found that the drug met its primary endpoint, achieving a survival benefit. PAX-101 is intended to ...
TARRYTOWN, NY / ACCESSWIRE / August 27, 2024 / PaxMedica, Inc. (OTC PINK:PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to ...
PURPOSE: To test the hypothesis that the efficacy and toxicity of suramin in the treatment of patients with hormone-refractory prostate cancer was dose dependent. PATIENTS AND METHODS: Patients were ...
PURPOSE: To determine the toxicity, efficacy, and pharmacology of suramin in patients with recurrent or progressive recurrent high-grade gliomas. PATIENTS AND METHODS: Fifty adults were to receive ...
PaxMedica, Inc. is a forward-looking clinical-stage biopharmaceutical firm specializing in developing cutting-edge, anti-purinergic drug therapies (APT) aimed at addressing a range of challenging ...
TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading biopharmaceutical company dedicated to advancing treatments for neurological ...
PaxMedica, Inc. is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (APT) aimed at addressing a range of challenging neurologic ...
BOSTON, MA / ACCESSWIRE / January 14, 2025 / PaxMedica, Inc. (PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, is pleased to announce it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback